Capitalization 4B 29.08B 335B P/E ratio 2022
-79.4x
P/E ratio 2023 -56.5x
Enterprise value 3.67B 26.66B 307B EV / Sales 2022
33x
EV / Sales 2023 42.4x
Free-Float
41.54%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day+4.88%
1 week+18.78%
Current month+45.27%
1 month+17.49%
3 months-61.88%
6 months-75.98%
Current year-78.50%
More quotes
1 week
1.81
Extreme 1.81
2.27
1 month
1.43
Extreme 1.43
2.27
Current year
1.43
Extreme 1.43
11.50
1 year
1.43
Extreme 1.43
12.50
3 years
1.43
Extreme 1.43
24.33
5 years
1.43
Extreme 1.43
24.33
10 years
1.43
Extreme 1.43
26.55
More quotes
Insider TitleAgeSince
Chief Executive Officer 38 01/16/01
Chairman 48 01/08/01
Director/Board Member 66 01/10/01
Insider TitleAgeSince
Founder 72 16/96/16
Director/Board Member 65 28/08/28
Director/Board Member 50 01/03/01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+4.88%+18.78%-76.58%-70.71% 113M
+1.11%+2.54%+47.61%+133.35% 45.92B
-0.60%+4.01%+40.95%+65.73% 25.89B
+1.13%+1.80% - - 16.69B
+0.37%-0.46%+43.33%+58.60% 14.45B
+2.66%-0.45%+92.34%+91.70% 13.81B
-.--%+0.14% - - 6.79B
-1.11%+0.50%-12.84%-11.30% 6.78B
+0.22%+1.38%+23.88%+37.59% 5.73B
-.--%-1.95% - - 5.73B
Average +0.87%+1.58%+22.67%+43.57% 14.19B
Weighted average by Cap. +0.64%+1.24%+46.04%+89.35%
See all sector performances

Financials

Ratios2022 2023
Net sales 123M 893M 10.29B 86.62M 629M 7.25B
Net income -56.12M -408M -4.7B -70.94M -515M -5.94B
Net Debt -403M -2.93B -33.75B -333M -2.42B -27.89B
More financial data * Estimated data
Logo Kunming Longjin Pharmaceutical Co., Ltd.
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.
Employees
285
Calendar
More about the company
Date Price Change Volume
24/24/24 2.150 ¥ +4.88% 20,192,900
23/24/23 2.050 ¥ -5.09% 23,467,600
22/24/22 2.160 ¥ +4.85% 14,326,980
19/24/19 2.060 ¥ +5.10% 19,917,030
18/24/18 1.960 ¥ +3.16% 27,920,170

End-of-day quote Shenzhen S.E., July 24, 2024

More quotes
  1. Stock Market
  2. Equities
  3. 002750 Stock